Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
- First Posted Date
- 2024-12-05
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 36
- Registration Number
- NCT06717815
- Locations
- 🇨🇳
Hebei Petro China Central Hospital, Langfang, Hebei, China
🇨🇳Xinxiang Central Hospital, Xinxiang, Henan, China
🇨🇳The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Phase 1 Study for IPG11406 in Health Volunteer
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 66
- Registration Number
- NCT06255834
- Locations
- 🇨🇳
Zhejiang Hospital, Hangzhou, Zhejiang, China
Phase I/II Study of IPG1094 in Advanced Solid Tumors Patients
- First Posted Date
- 2024-01-18
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 60
- Registration Number
- NCT06212076
- Locations
- 🇨🇳
Shanghai GoBroad Cancer Hospital China Pharmaceutical University, Shanghai, China
🇨🇳Shanghai General Hospital, Shanghai, Shanghai, China
A Study of Orally Administered IPG7236 in Healthy Adult Participants
- Conditions
- Atopic Dermatitis
- Interventions
- Other: Placebo (Part A)Drug: IPG7236- Single ascending doseDrug: IPG7236- Multiple ascending dose
- First Posted Date
- 2022-03-21
- Last Posted Date
- 2022-04-07
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 86
- Registration Number
- NCT05288543
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Nanjing Immunophage Biotech Co., Ltd
- Target Recruit Count
- 196
- Registration Number
- NCT05142592
- Locations
- 🇺🇸
Providence Portland Medical Center, Portland, Oregon, United States
🇨🇳The First Affiliated Hospital Nanchang Univeristy, Nanchang, Jiangxi, China
🇨🇳Shandong Cancer Hospital, Jinan, Shangdong, China
- Prev
- 1
- 2
- Next